Does Anakinra Interact with Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate?
Anakinra and Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate have a major drug interaction according to U.S. FDA drug labeling data. Coadministration with rilpivirine requires staggered administration due to increased gastric pH potentially decreasing rilpivirine plasma concentrations and loss of virologic response. The mechanism involves increased gastric ph decreases rilpivirine absorption. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Anakinra Class
- Interleukin-1 Receptor Antagonist
- Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Anakinra and Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate occurs because increased gastric ph decreases rilpivirine absorption. Clinically, this means coadministration with rilpivirine requires staggered administration due to increased gastric ph potentially decreasing rilpivirine plasma concentrations and loss of virologic response. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Anakinra and your doctor is considering prescribing Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider